SpringWorks Therapeutics (SWTX) Stock Forecast, Price Target & Predictions
SWTX Stock Forecast
SpringWorks Therapeutics stock forecast is as follows: an average price target of $76.00 (represents a 113.54% upside from SWTX’s last price of $35.59) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
SWTX Price Target
The average price target for SpringWorks Therapeutics (SWTX) is $76.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $76.00 to $76.00. This represents a potential 113.54% upside from SWTX's last price of $35.59.
SWTX Analyst Ratings
According to 3 Wall Street analysts, SpringWorks Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SWTX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
SpringWorks Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Robert Burns | H.C. Wainwright | $76.00 | $33.93 | 123.99% | 113.54% |
| Aug 09, 2022 | H.C. Wainwright | $94.00 | $39.66 | 137.01% | 164.12% | |
| May 27, 2022 | Wedbush | $50.00 | $18.72 | 167.09% | 40.49% | |
| May 24, 2022 | Goldman Sachs | $76.00 | $32.74 | 132.13% | 113.54% |
The latest SpringWorks Therapeutics stock forecast, released on Aug 08, 2024 by Robert Burns from H.C. Wainwright, set a price target of $76.00, which represents a 123.99% increase from the stock price at the time of the forecast ($33.93), and a 113.54% increase from SWTX last price ($35.59).
SpringWorks Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $76.00 |
| Last Closing Price | $35.59 | $35.59 | $35.59 |
| Upside/Downside | -100.00% | -100.00% | 113.54% |
In the current month, the average price target of SpringWorks Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to SpringWorks Therapeutics's last price of $35.59. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 18, 2022 | H.C. Wainwright | Buy | Buy | Hold |
| May 27, 2022 | Wedbush | Outperform | Outperform | Hold |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
SpringWorks Therapeutics's last stock rating was published by H.C. Wainwright on Aug 08, 2024. The company gave SWTX a "Buy" rating, the same as its previous rate.
SpringWorks Therapeutics Financial Forecast
SpringWorks Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $5.45M | - | - | $35.00M |
| Avg Forecast | $113.57M | $97.14M | $82.95M | $68.88M | $55.39M | $53.28M | $34.42M | $12.07M | $860.19K | $3.82M | $180.00 | $21.00M |
| High Forecast | $135.78M | $116.15M | $99.18M | $87.53M | $65.81M | $53.43M | $34.42M | $12.07M | $1.57M | $4.59M | $216.00 | $21.00M |
| Low Forecast | $87.43M | $74.79M | $63.86M | $57.34M | $35.18M | $53.14M | $34.42M | $12.07M | $498.36K | $3.06M | $144.00 | $21.00M |
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 2 | 2 | 4 | 17 | 17 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | 6.33% | - | - | 1.67% |
SpringWorks Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $12.07M, with a low forecast of $12.07M, and a high forecast of $12.07M. SWTX's average Quarter revenue forecast represents a 121.56% increase compared to the company's last Quarter revenue of $5.45M (Dec 23).
SpringWorks Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 2 | 2 | 4 | 17 | 17 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | $-97.92M | $-61.36M | $-29.68M | $11.38M |
| Avg Forecast | $-22.71M | $-19.43M | $-16.59M | $-13.78M | $-11.08M | $-10.66M | $-6.88M | $-2.41M | $-172.04K | $-47.26B | $-23.25M | $-4.20M |
| High Forecast | $-17.49M | $-14.96M | $-12.77M | $-11.47M | $-7.04M | $-10.63M | $-6.88M | $-2.41M | $-99.67K | $-37.81B | $-18.60M | $-4.20M |
| Low Forecast | $-27.16M | $-23.23M | $-19.84M | $-17.51M | $-13.16M | $-10.69M | $-6.88M | $-2.41M | $-314.04K | $-56.71B | $-27.90M | $-4.20M |
| Surprise % | - | - | - | - | - | - | - | - | 569.21% | 0.00% | 1.28% | -2.71% |
17 analysts predict SWTX's average Quarter EBITDA for Mar 21 to be $-23.25M, with a high of $-18.60M and a low of $-27.90M. This is -304.29% lower than SpringWorks Therapeutics's previous annual EBITDA (Dec 20) of $11.38M.
SpringWorks Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 2 | 2 | 4 | 17 | 17 | 10 |
| Net Income | - | - | - | - | - | - | - | - | $-94.32M | $-62.13M | $-29.79M | $11.27M |
| Avg Forecast | $-26.53M | $-36.52M | $-45.23M | $-53.44M | $-48.31M | $-55.97M | $-82.89M | $-87.03M | $-91.84M | $-47.26B | $-23.36M | $-6.18M |
| High Forecast | $-18.59M | $-25.60M | $-31.70M | $-33.12M | $-35.13M | $-39.23M | $-58.09M | $-60.99M | $-87.43M | $-37.81B | $-18.69M | $-6.18M |
| Low Forecast | $-33.28M | $-45.81M | $-56.74M | $-73.01M | $-57.09M | $-70.20M | $-103.96M | $-109.16M | $-98.45M | $-56.71B | $-28.03M | $-6.18M |
| Surprise % | - | - | - | - | - | - | - | - | 1.03% | 0.00% | 1.28% | -1.82% |
SpringWorks Therapeutics's average Quarter net income forecast for Mar 21 is $-23.36M, with a range of $-28.03M to $-18.69M. SWTX's average Quarter net income forecast represents a -307.26% decrease compared to the company's last Quarter net income of $11.27M (Dec 20).
SpringWorks Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 2 | 2 | 4 | 17 | 17 | 10 |
| SG&A | - | - | - | - | - | - | - | - | $59.84M | $27.37M | $12.38M | $8.52M |
| Avg Forecast | $1.39B | $1.19B | $1.01B | $840.28M | $675.79M | $650.03M | $419.89M | $147.23M | $10.49M | $46.65M | $2.19K | $256.19M |
| High Forecast | $1.66B | $1.42B | $1.21B | $1.07B | $802.82M | $651.78M | $419.89M | $147.24M | $19.16M | $55.98M | $2.63K | $256.19M |
| Low Forecast | $1.07B | $912.38M | $779.09M | $699.53M | $429.17M | $648.29M | $419.89M | $147.23M | $6.08M | $37.32M | $1.76K | $256.19M |
| Surprise % | - | - | - | - | - | - | - | - | 5.70% | 0.59% | 5640.55% | 0.03% |
SpringWorks Therapeutics's average Quarter SG&A projection for Mar 24 is $147.23M, based on 2 Wall Street analysts, with a range of $147.23M to $147.24M. The forecast indicates a 146.06% rise compared to SWTX last annual SG&A of $59.84M (Dec 23).
SpringWorks Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Mar 22 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 2 | 2 | 4 | 17 | 17 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.27 | $-0.62 | $0.26 |
| Avg Forecast | $-0.36 | $-0.49 | $-0.61 | $-0.72 | $-0.65 | $-0.75 | $-1.12 | $-1.17 | $-1.24 | $-1.02 | $-0.51 | $-0.08 |
| High Forecast | $-0.25 | $-0.34 | $-0.43 | $-0.45 | $-0.47 | $-0.53 | $-0.78 | $-0.82 | $-1.18 | $-1.02 | $-0.51 | $-0.08 |
| Low Forecast | $-0.45 | $-0.62 | $-0.76 | $-0.98 | $-0.77 | $-0.95 | $-1.40 | $-1.47 | $-1.33 | $-1.02 | $-0.51 | $-0.08 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.24% | 1.22% | -3.12% |
According to 17 Wall Street analysts, SpringWorks Therapeutics's projected average Quarter EPS for Mar 21 is $-0.51, with a low estimate of $-0.51 and a high estimate of $-0.51. This represents a -296.15% decrease compared to SWTX previous annual EPS of $0.26 (Dec 20).
SpringWorks Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| SANA | Sana Bio | $1.91 | $8.00 | 318.85% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| ARVN | Arvinas | $19.10 | $58.50 | 206.28% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| PLRX | Pliant Therapeutics | $14.37 | $35.50 | 147.04% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| SWTX | SpringWorks Therapeutics | $37.72 | $76.00 | 101.48% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| RNA | Avidity Biosciences | $32.74 | $59.00 | 80.21% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| KYMR | Kymera Therapeutics | $42.30 | $58.60 | 38.53% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |